Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Emcure Pharmaceuticals Business Update

Emcure Pharmaceuticals received an Establishment Inspection Report (EIR) from the USFDA, classifying its Sanand facility inspection as 'Voluntary Action Indicated' and effectively closing the inspection.

Source

NSE filing, NSE: EMCURE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Emcure Pharmaceuticals Ltd: key numbers

Share price
₹1,875.00
Market cap
₹35,571 Cr
Revenue (annual)
₹9,204 Cr
Net profit (annual)
₹924.4 Cr
P/E (TTM)
35.2×Sector 46.1×
Promoter holding
77.82%-0.01% QoQ
FII holding
4.94%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Emcure Pharmaceuticals Ltd

All →

Other business update announcements

All →